Geron
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Geron and other ETFs, options, and stocks.About GERN
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies.
GERN Key Statistics
GERN News
Key Insights Geron to hold its Annual General Meeting on 9th of May Total pay for CEO Chip Scarlett includes US$787.0k salary The total compensation is 31% l...
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024, 8:00 a.m. ET Contents: Prepared Remarks Questions and Answers Cal...
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share...
Analyst ratings
86%
of 7 ratingsMore GERN News
Reports Q1 revenue $304,000, consensus $20,000. “Since the FDA ODAC’s 12 to 2 vote in favor of the clinical benefit/risk profile of imetelstat for the treatment...
June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS FOSTER CITY, Calif., May 02...
Baird has downgraded Geron (NASDAQ:GERN) to neutral over valuation concerns following a recent run-up in the stock. The investment firm said that while it stil...
Baird downgraded Geron to Neutral from Outperform with an unchanged price target of $4.50. After the stock’s recent run-up, the firm sees Geron’s risk/reward as...
Loading... Loading... Geron GERN has been analyzed by 10 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish....
